Abstract:Pulmonary computed tomography (CT) scans are commonly used as part of the clinical criteria in diagnostic workup of invasive fungal diseases like invasive aspergillosis, and may identify radiographic abnormalities, such as halo signs or air-crescent signs. We assessed the diagnostic utility of CT assessment in patients with hematologic malignancies or those who had undergone allogeneic hematopoietic stem cell transplantation in whom invasive aspergillosis was suspected. This post-hoc analysis assessed data from a prospective, multicenter, international trial of voriconazole (with and without anidulafungin) in patients with suspected invasive aspergillosis (IA; proven, probable, or possible, using 2008 European Organisation for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group criteria) [NCT00531479]. Eligible patients received at least one baseline lung CT scan. Of 395 patients included in this post-hoc analysis, 240 patients (60.8%) had ‘confirmed’ proven (9/240, 3.8%) or probable (231/240, 96.3%) invasive aspergillosis (cIA) and 155 patients (39.2%) had ‘non-confirmed’ invasive aspergillosis (all nIA; all possible IA (de Pauw et al., Clin Infect Dis 46:1813–21, 2008)). Mean age was 52.3 and 50.5 years, 56.3 and 60.0% of patients were male, and most patients were white (71.7 and 71.0%) in the cIA and nIA populations, respectively. Median baseline galactomannan was 1.4 (cIA) and 0.2 (nIA), mean Karnofsky score was 65.3 (cIA) and 66.8 (nIA), and mean baseline platelet count was 48.0 (cIA) and 314.1 (nIA). Pulmonary nodules (46.8% of all patients), bilateral lung lesions (37.5%), unilateral lung lesions (28.4%), and consolidation (24.8%) were the most common radiographic abnormalities. Ground-glass attenuation (cIA: 24.2%; nIA: 11.6%; P < 0.01) and pulmonary nodules (cIA: 52.5%; nIA: 38.1%; P < 0.01) were associated with cIA. Other chest CT scan abnormalities (including halo signs and air-crescent signs) at baseline in patients with hematologic malignancy or hematopoietic stem cell transplantation, and suspected IA, were not associated with cIA. These findings highlight the limitations in the sensitivity of chest CT scans for the diagnosis of IA, and reinforce the importance of incorporating other available clinical data to guide management decisions on individual patients, including whether empirical treatment is reasonable, pending full evaluation. NCT00531479 (First posted on ClinicalTrials.gov on September 18, 2007)

[The Value of Serum Galactomannan Detection for Diagnosis of Invasive Aspergillosis in Hematopoietic Stem Cell Transplant Recipients].

[Evaluation of the Galactomannan Assay for the Diagnosis of Invasive Aspergillosis in Patients].

Detection Of Galactomannan And (1-3)-Beta-D-Glucan For Early Diagnosis Of Invasive Aspergillosis In Hematological Cancer Patients

A Systematic Review of the Accuracy of Diagnostic Test of Serum Galactomannan Antigen Detection for Invasive Aspergillosis

[Combination of Real-Time Polymerase Chain Reaction Assay and Serum Galactomannan in the Diagnosis of Invasive Aspergillosis in Patients with Hematological Malignancies and Recipients of Hematopoietic Stem Cell Transplantation].

Diagnostic performance of serum galactomannan and β-D-glucan for invasive aspergillosis in suspected patients: A meta-analysis

Serum galactomannan test for diagnosis of invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease

[Serum Antigens Assay Combined with Chest CT Scan in Diagnosis of Invasive Pulmonary Aspergillosis].

Diagnostic Value of Galactomannan Antigen Test in Serum and Bronchoalveolar Lavage Fluid Samples from Patients with Nonneutropenic Invasive Pulmonary Aspergillosis.

Serum Galactomannan Level for the Diagnosis of Invasive Pulmonary Aspergillosis in Hospitalized Patients with Chronic Obstructive Pulmonary Disease (COPD): Meta-analysis

The diagnosis of invasive and noninvasive pulmonary aspergillosis by serum and bronchoalveolar lavage fluid galactomannan assay.

Utility Of Computed Tomography For The Diagnosis Of Invasive Aspergillosis In Hematological Malignancy

Utility of CT Assessment in Hematology Patients with Invasive Aspergillosis: a Post-Hoc Analysis of Phase 3 Data

The Application of Real-time PCR in Invasive Aspergillosis Diagnosis

Diagnostic Value of Serum Biomarkers for Invasive Aspergillosis in Haematologic Patients

Performance of the clarus Aspergillus galactomannan enzyme immunoassay prototype for the diagnosis of invasive pulmonary aspergillosis in serum

Value of Serum Galactomannan Enzyme Immunoassay Combine with 1, 3 Beta-Glucan Assay for Diagnosis of Invasive Fungal Infection in Hematological Disorders

Evaluation of the JF5-based Aspergillus galactomannoprotein lateral flow device for diagnosing invasive aspergillosis in cancer patients

Quantitative Real-Time PCR and Platelia Galactomannan Assay for the Diagnosis of Invasive Pulmonary Aspergillosis: Bronchoalveolar Lavage Fluid Performs Better Than Serum in Non-neutropaenic Patients

Performance of the sōna Aspergillus Galactomannan Lateral Flow Assay in a Cancer Patient Population

The clinical value of Aspergillus -specific IgG antibody test in the diagnosis of nonneutropenic invasive pulmonary aspergillosis